Bi-Ventricular Pacing Improves Ejection Fraction and Ventricular Size in Systolic Heart Failure Patients Treated at a Community Referral Hospital

2010 ◽  
Vol 16 (8) ◽  
pp. S115
Author(s):  
Kalki Bommaraju ◽  
Lee W. Jordan
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Systolic Heart Failure ◽  
Referral Hospital ◽  
Ventricular Size ◽  
Ventricular Pacing ◽  
Heart Failure Patients

P781Resveratrol improves cardiac function and exerts an anti-inflammatory effect in systolic heart failure patients

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
R Halmosi ◽  
R Gal ◽  
L Deres ◽  
O Horvath ◽  
Z S Marton ◽  
...  
Keyword(s):  
Heart Failure ◽  
Placebo Group ◽  
Ejection Fraction ◽  
Inflammatory Cytokines ◽  
Medical Therapy ◽  
Systolic Heart Failure ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Heart Failure Patients ◽  
Galectin 3

Abstract Introduction The positive effects of resveratrol on heart failure have already been evaluated in several experimental animal models, however, in a human clinical trial it was not yet confirmed. The aim of our study was to assess the effect of resveratrol supplementation on left ventricular structure and function in patients with heart failure with reduced ejection fraction (HFrEF). Methods and materials 60 HFrEF patients (age: 66.7±11.04 years, 17 women and 43 men) were enrolled into our study. They were randomized into two groups, in the first group (n=30) daily 2x50 mg resveratrol was administered orally and placebo was given in the other group (n=30). 56% of the enrolled patients had ischemic HFrEF. During the whole study period, patients were taken the optimal medical therapy of HFrEF (ACEI/ARB, BB, MRA) in the same dose as before the randomization. On the day of randomization and 3 months later echocardiography, six minutes walking test (6MWT) and quality of life questionnaire (QoL) test were performed. Besides the routine lab tests, the levels of biomarkers (NT-proBNP, galectin-3) and inflammatory cytokines (IL-1, IL-6) were also measured. Results After the 3-month-long follow-up period left ventricular ejection fraction improved significantly in the resveratrol group comparing to the placebo group (p<0.001). The function of the right ventricle (RV) improved (p<0.05), moreover the RV dimensions, as well as atrial volumes decreased significantly in the resveratrol group (p<0.05). In the case of 6MWT (p<0.05) and QoL test (p<0.05) a significant improvement could be observed in the resveratrol group versus the placebo group (p<0.05). Lab test analysis showed that resveratrol supplementation reduced significantly the total cholesterol level (p<0,05) and LDL-C level (p<0,05) and had no overt effect on other metabolic parameters. NT-proBNP level increased significantly in the placebo group (p<0.05) by the end of the trial, however, in the resveratrol group we could see a slight improving tendency (NS). In the case of Galectin-3, no significant changes could be seen. Conclusions Our results revealed that resveratrol supplementation in systolic heart failure patients adding to the standard medical therapy resulted in an improvement of echocardiographic parameters, functional status and decreased the level of inflammatory cytokines. Acknowledgement/Funding GINOP-2.3.2-15-2016-00048

Galectin-3 in Heart Failure – Linking Fibrosis, Remodelling and Progression

2010 ◽  
Vol 6 (2) ◽  
pp. 33 ◽  
Author(s):  
Christopher R deFilippi ◽  
G Michael Felker ◽  
◽  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Risk Stratification ◽  
Cardiac Fibrosis ◽  
The Elderly ◽  
Preserved Ejection Fraction ◽  
Heart Failure Patients ◽  
Large Populations ◽  
Galectin 3

For many with heart failure, including the elderly and those with a preserved ejection fraction, both risk stratification and treatment are challenging. For these large populations and others there is increasing recognition of the role of cardiac fibrosis in the pathophysiology of heart failure. Galectin-3 is a novel biomarker of fibrosis and cardiac remodelling that represents an intriguing link between inflammation and fibrosis. In this article we review the biology of galectin-3, recent clinical research and its application in the management of heart failure patients.

ACCESSMENT OF RIGHT VENTRICULAR SYSTOLIC FUNCTION USING TAPSE

2011 ◽  
pp. 62-70
Author(s):  
Lien Nhut Nguyen ◽  
Anh Vu Nguyen
Keyword(s):  
Heart Failure ◽  
Left Ventricular Ejection Fraction ◽  
Ejection Fraction ◽  
Right Ventricular ◽  
Systolic Function ◽  
Systolic Heart Failure ◽  
Left Ventricular ◽  
Ventricular Ejection ◽  
Left Ventricular Ejection ◽  
Ventricular Ejection Fraction

Background: The prognostic importance of right ventricular (RV) dysfunction has been suggested in patients with systolic heart failure (due to primary or secondary dilated cardiomyopathy - DCM). Tricuspid annular plane systolic excursion (TAPSE) is a simple, feasible, reality, non-invasive measurement by transthoracic echocardiography for evaluating RV systolic function. Objectives: To evaluate TAPSE in patients with primary or secondary DCM who have left ventricular ejection fraction ≤ 40% and to find the relation between TAPSE and LVEF, LVDd, RVDd, RVDd/LVDd, RA size, severity of TR and PAPs. Materials and Methods: 61 patients (36 males, 59%) mean age 58.6 ± 14.4 years old with clinical signs and symtomps of chronic heart failure which caused by primary or secondary DCM and LVEF ≤ 40% and 30 healthy subject (15 males, 50%) mean age 57.1 ± 16.8 were included in this study. All patients and controls were underwent echocardiographic examination by M-mode, two dimentional, convensional Dopler and TAPSE. Results: TAPSE is significant low in patients compare with the controls (13.93±2.78 mm vs 23.57± 1.60mm, p<0.001). TAPSE is linearly positive correlate with echocardiographic left ventricular ejection fraction (r= 0,43; p<0,001) and linearly negative correlate with RVDd (r= -0.39; p<0.01), RVDd/LVDd (r=-0.33; p<0.01), RA size (r=-0.35; p<0.01), TR (r=-0.26; p<0.05); however, no correlation was found with LVDd and PAPs. Conclusions: 1. Decreased RV systolic function as estimated by TAPSE in patients with systolic heart failure primary and secondary DCM) compare with controls. 2. TAPSE is linearly positive correlate with LVEF (r= 0.43; p<0.001) and linearly negative correlate with RVDd (r= -0.39; p<0.01), RVDd/LVDd (r=-0.33; p<0.01), RA size (r=-0.35; p<0.01), TR (r=-0.26; p<0.05); however, no correlation is found with LVDd and PAPs. 3. TAPSE should be used routinely as a simple, feasible, reality method of estimating RV function in the patients systolic heart failure DCM (primary and secondary).

scholarly journals Relationship of anemia and clinical outcome in heart failure patients with preserved versus reduced ejection fraction in a rural area of Thailand

2020 ◽  
Vol 30 ◽  
pp. 100597
Author(s):  
Kittayaporn Chairat ◽  
Wipharak Rattanavipanon ◽  
Krittika Tanyasaensook ◽  
Busba Chindavijak ◽  
Suvatna Chulavatnatol ◽  
...  
Keyword(s):  
Heart Failure ◽  
Clinical Outcome ◽  
Ejection Fraction ◽  
Rural Area ◽  
Reduced Ejection Fraction ◽  
Heart Failure Patients ◽  
Relationship Of
Sign in / Sign up

Export Citation Format

Share Document